Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.74 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.74 |
| ▸ | GAA | P10253 | 2/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.74 |
| ▸ | TP53 | P04637 | 1/20 | 0.74 |
| ▸ | GLA | P06280 | 1/20 | 0.74 |
| ▸ | MAPT | P10636 | 1/20 | 0.74 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.74 |
| ▸ | LIPE | Q05469 | 2/20 | 0.52 |
| ▸ | FLT1 | P17948 | 4/20 | 0.51 |
| ▸ | FLT4 | P35916 | 4/20 | 0.51 |
| ▸ | KDR | P35968 | 4/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glyclopyramide SCHEMBL49354 | 0.98 | ALDH1A1 (0.71) | ALDH1A1CYP3A4NFKB1GAAKDM4E | |
| Glyclopyramide SCHEMBL15669226 | 0.98 | ALDH1A1 (0.71) | ALDH1A1CYP3A4NFKB1GAAKDM4E | |
| Tolazamide SCHEMBL34417 | 0.85 | ALDH1A1 (1.00) | ALDH1A1CYP3A4NFKB1GAAKDM4E | |
| Tolazamide SCHEMBL13725632 | 0.85 | ALDH1A1 (1.00) | ALDH1A1CYP3A4NFKB1GAAKDM4E | |
| Tolazamide SCHEMBL2534564 | 0.84 | ALDH1A1 (0.70) | ALDH1A1CYP3A4NFKB1GAAKDM4E | |
| Tolazamide SCHEMBL28562527 | 0.84 | ALDH1A1 (0.97) | ALDH1A1CYP3A4NFKB1GAAKDM4E | |
| SCHEMBL11627200 | 0.83 | MCHR1 (0.59) | ALDH1A1CYP3A4NFKB1GAAKDM4E | |
| SCHEMBL11626350 | 0.83 | MCHR1 (0.59) | ALDH1A1CYP3A4NFKB1GAAKDM4E | |
| Glypinamide SCHEMBL5243890 | 0.82 | ALDH1A1 (0.59) | ALDH1A1CYP3A4NFKB1GAAKDM4E | |
| Acetohexamide SCHEMBL20267964 | 0.82 | ALDH1A1 (0.73) | ALDH1A1CYP3A4NFKB1GAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1820 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12208071-B2 | Glucagon receptor antagonists | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2025-01-28 | — | — | US | claimed |
| US-20210121422-A1 | GLUCAGON RECEPTOR ANTAGONISTS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2021-04-29 | — | — | US | claimed |
| EP-3752249-A1 | GLUCAGON RECEPTOR ANTAGONISTS | Ligand Pharmaceuticals, Inc. (US) | 2020-12-23 | — | — | EP | claimed |
| WO-2019160940-A1 | GLUCAGON RECEPTOR ANTAGONISTS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2019-08-22 | — | — | WO | claimed |
| US-20190194143-A1 | GLUCAGON RECEPTOR ANTAGONISTS | LIGAND PHARM INC (US) | 2019-06-27 | — | — | US | claimed |
| EP-3500565-A1 | GLUCAGON RECEPTOR ANTAGONISTS | Ligand Pharmaceuticals, Inc. (US) | 2019-06-26 | — | — | EP | claimed |
| WO-2018035172-A1 | GLUCAGON RECEPTOR ANTAGONISTS | LIGAND PHARMACEUTICALS, INC. (US) | 2018-02-22 | — | — | WO | claimed |
| US-9359339-B2 | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | MERCK SHARP & DOHME CORP. (US) | 2016-06-07 | — | — | US | claimed |
| EP-2346830-B1 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK SHARP & DOHME (US) | 2015-05-13 | — | — | EP | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| WO-2002015892-A2 | COMBINATION COMPRISING AN INSULIN SECRETION ENHANCER AND AN ACTIVE INGREDIENT SELECTED FROM HMG-CO-A REDUCTASE INHIBITORS AND ACE INHIBITORS | NOVARTIS AG (CH) | 2002-02-28 | — | — | WO | claimed |
| US-6329404-B1 | Pharmaceutical composition | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-12-11 | — | — | US | claimed |
| US-6303640-B1 | ADMINISTERING OXAZOLE OR THIAZOLE DERIVATIVE COMPOUND FOR REDUCING SIDE EFFECTS OF DIABETIC THERAPY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-10-16 | — | — | US | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| US-6211205-B1 | ANTIDIABETIC AGENTS THAT ENHANCE INSULIN SECRETION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-04-03 | — | — | US | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| US-6150383-A | COMPRISING AN INSULIN SENSITIVITY ENHANCER IN COMBINATION WITH ONE OR MORE OTHER ANTIDIABETICS DIFFERING FROM THE ENHANCER IN MECHANISM OF ACTION; LIPID/GLYCOMETABOLISM DISORDERS; ANTIDIABETIC AGENTS; SIDE EFFECT REDUCTION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-11-21 | — | — | US | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-5656286-A | BLEND OF TWO POLYMERS; PRESSURE SENSITIVE ADHESIVE | NOVEN PHARMACEUTICALS, INC. (US) | 1997-08-12 | — | — | US | claimed |
| US-4346709-A | Drug delivery devices comprising erodible polymer and erosion rate modifier | ALZA CORPORATION (US) | 1982-08-31 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210121422-A1 | GLUCAGON RECEPTOR ANTAGONISTS | GLP1R, GCGR, GCG | ALDH1A1 4216/4885CYP3A4 1256/4885NFKB1 3537/4885 |
| US-12208071-B2 | Glucagon receptor antagonists | GLP1R, GCGR, GCG | ALDH1A1 4216/4885CYP3A4 1256/4885NFKB1 3537/4885 |
| US-20190194143-A1 | GLUCAGON RECEPTOR ANTAGONISTS | GLP1R, GCGR, GCG | ALDH1A1 4284/4885CYP3A4 1204/4885NFKB1 3317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.